Scarica l'app Stockscreener
5.33
1.84%
-0.10
Dopo l'orario di chiusura:
5.40
0.07
+1.31%
Precedente Chiudi:
$5.43
Aprire:
$5.34
Volume 24 ore:
252.00K
Relative Volume:
0.46
Capitalizzazione di mercato:
$424.65M
Reddito:
$351.37M
Utile/perdita netta:
$-158.35M
Rapporto P/E:
-2.7301
EPS:
-1.9523
Flusso di cassa netto:
$-132.03M
1 W Prestazione:
-11.17%
1M Prestazione:
+13.89%
6M Prestazione:
+81.91%
1 anno Prestazione:
+67.61%
Intervallo 1D:
$5.32
$5.508
Intervallo di 1 settimana:
$5.05
$6.05
Portata 52W:
$2.455
$6.45
Atea Pharmaceuticals Inc Stock (AVIR) Company Profile
Nome
Atea Pharmaceuticals Inc
Settore
Industria
Telefono
(857) 284-8891
Indirizzo
225 FRANKLIN STREET, BOSTON
Compare AVIR vs VRTX, REGN, ALNY, ARGX, INSM
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
AVIR
Atea Pharmaceuticals Inc
|
5.33 | 432.62M | 351.37M | -158.35M | -132.03M | -1.9523 |
VRTX
Vertex Pharmaceuticals Inc
|
453.74 | 115.58B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
756.73 | 79.23B | 14.34B | 4.50B | 3.77B | 41.56 |
ALNY
Alnylam Pharmaceuticals Inc
|
328.16 | 43.59B | 3.71B | 313.75M | 465.38M | 2.2571 |
ARGX
Argen X Se Adr
|
692.83 | 43.26B | 4.16B | 1.29B | 734.26M | 19.58 |
INSM
Insmed Inc
|
147.60 | 31.97B | 606.42M | -1.28B | -997.58M | -6.403 |
Atea Pharmaceuticals Inc Stock (AVIR) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-08-13 | Aggiornamento | Morgan Stanley | Underweight → Equal-Weight |
| 2023-08-10 | Downgrade | JP Morgan | Neutral → Underweight |
| 2022-01-06 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| 2021-11-18 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| 2021-10-20 | Downgrade | JP Morgan | Overweight → Neutral |
| 2021-10-05 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2020-11-25 | Iniziato | Evercore ISI | Outperform |
| 2020-11-24 | Iniziato | JP Morgan | Overweight |
| 2020-11-24 | Iniziato | Morgan Stanley | Overweight |
| 2020-11-24 | Iniziato | William Blair | Outperform |
Mostra tutto
Atea Pharmaceuticals Inc Borsa (AVIR) Ultime notizie
Vanguard disaggregation leaves Atea stake at 0% (NYSE: AVIR) - Stock Titan
ReAlta revamps leadership as pegtarazimod nears late-stage trials - Stock Titan
Stock Recap: Is Atea Pharmaceuticals Inc attractive for institutional investorsWatch List & Free Weekly Watchlist of Top Performers - baoquankhu1.vn
If You Invested $1,000 in Atea Pharmaceuticals, Inc. (AVIR) - Stock Titan
Published on: 2026-03-20 02:34:07 - baoquankhu1.vn
AVIR Forecast, Price Target & Analyst Ratings | ATEA PHARMACEUTICALS INC (NASDAQ:AVIR) - ChartMill
Top 2 Health Care Stocks That May Fall Off A Cliff This Month - Benzinga
AVIR Earning Date, Earning Analysis and Earning Prediction - Intellectia AI
Hedge Fund Bets: Can Atea Pharmaceuticals Inc stock double in the next yearEarnings Summary Report & Precise Buy Zone Identification - baoquankhu1.vn
Atea Pharmaceuticals (NASDAQ: AVIR) officer exercises options for 60,000 shares - Stock Titan
Atea Pharmaceuticals (NASDAQ:AVIR) Hits New 12-Month HighHere's Why - MarketBeat
Atea Pharma presents data on compounds for hepatitis E - BioWorld MedTech
Atea Pharmaceuticals (AVIR) Price Target Raised by Evercore ISI - GuruFocus
Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) Q4 2025 Earnings Call Transcript - Insider Monkey
Here's Why I Wouldn't Touch Amarin With a 10‑Foot Pole Given Its Patent and Competition Risks - AOL.com
AVIR PE Ratio & Valuation, Is AVIR Overvalued - Intellectia AI
Atea Pharmaceuticals’ Earnings Call Flags Pivotal 2026 - TipRanks
Can Atea Pharmaceuticals Inc stock double in the next year2025 Winners & Losers & Consistent Income Trade Ideas - baoquankhu1.vn
Viridian Therapeutics Stock Up 75%, but One Fund Just Sold Off Its $69 Million Stake - AOL.com
Atea Pharmaceuticals, Inc. Q4 2025 Earnings Call Summary - Yahoo Finance
Atea Pharmaceuticals Q4 2025 Earnings Call Transcript - MarketBeat
Atea Pharmaceuticals, Inc. 2025 Q4ResultsEarnings Call Presentation (NASDAQ:AVIR) 2026-03-05 - Seeking Alpha
Atea Pharmaceuticals Q4 Earnings Call Highlights - MarketBeat
AVIR: Phase III HCV trials near completion, HEV pipeline expanded, and cash runway extends through 2027 - TradingView
Atea Pharma (AVIR) Earnings Call Transcript - AOL.com
Earnings call transcript: Atea Pharmaceuticals Q4 2025 sees stock rise despite EPS miss - Investing.com
AVIR: Phase 3 HCV trials near completion, with robust cash and new HEV candidate advancing - TradingView
Atea Pharmaceuticals (NASDAQ:AVIR) Posts Earnings Results, Misses Expectations By $0.08 EPS - MarketBeat
Atea Pharmaceuticals 10-K: $0 Revenue, $(158.3)M Net Loss - TradingView
Atea Pharmaceuticals : Q4 FY25 IR Slide Deck 3 5 26 FINAL - marketscreener.com
Atea Pharmaceuticals (Nasdaq: AVIR) narrows 2025 loss and advances HCV, HEV pipeline - Stock Titan
BRIEF-Atea Pharmaceuticals Q4 Basic EPS USD -0.57 - TradingView
Atea Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update - GlobeNewswire
Insights Ahead: Atea Pharmaceuticals's Quarterly Earnings - Benzinga
Risk Off: Can Atea Pharmaceuticals Inc navigate macro headwinds2025 Key Highlights & AI Driven Price Predictions - baoquankhu1.vn
Disc Medicine Stock Is Swinging, but This Fund's New $52 Million Bet Shows Conviction - AOL.com
What Investors Should Know About a $1.5 Million Apogee Insider Sale Amid a 60% Stock Rally - AOL.com
AVIR Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
Atea Pharmaceuticals to Host Fourth Quarter and Full Year 2025 Financial Results and Business Update Conference Call on March 5, 2026 - The Manila Times
Atea Pharmaceuticals to Host Fourth Quarter and Full Year - GlobeNewswire
AVIR SEC FilingsAtea Pharmaceuticals, Inc. 10-K, 10-Q, 8-K Forms - Stock Titan
Atea Pharmaceuticals (AVIR) to Release Quarterly Earnings on Thursday - Defense World
AVIR Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Atea Pharmaceuticals presents preclinical results of AT-587 - marketscreener.com
Atea Pharmaceuticals Presents Preclinical Results Supporting First-in-Class Potential of AT-587 for Treatment of Hepatitis E Virus at CROI 2026 - GlobeNewswire
No approved hepatitis E drugs: experimental pill shows powerful lab results - Stock Titan
BML Capital Management LLC Cuts Holdings in Atea Pharmaceuticals, Inc. $AVIR - Defense World
Apogee Stock Jumps 87% in One Year as This Biotech Fund Lifts Stake to $93 Million - AOL.com
Why Did Compass Pathways Stock Rocket Higher Today? - AOL.com
Is Atea Pharmaceuticals Inc. stock recession proofJuly 2025 Retail & Low Risk Entry Point Tips - mfd.ru
AVIR Should I Buy - Intellectia AI
Atea Pharmaceuticals Inc Azioni (AVIR) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.04%
0.06%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):